Literature DB >> 15240036

Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens.

V Cirimele1, S Etienne, M Villain, B Ludes, P Kintz.   

Abstract

A solid-phase enzyme immunoassay involving microtiter plates was recently proposed by International Diagnostic Systems corporation (IDS) to screen for buprenorphine in human serum. The performance of the kit led us to investigate its applicability in other biological matrices such as urine or blood, and also hair specimens. Low concentrations of buprenorphine were detected with the ELISA test and confirmed by HPLC/MS (buprenorphine concentrations measured by HPLC/MS: 0.3 ng/mL in urine, 0.2 ng/mL in blood, and 40 pg/mg in hair). The intra-assay precision values were 8.7% at 1 ng/mL of urine (n = 8), 11.5% at 2 ng/mL in serum (n = 8), and 11.5% at 250 pg/mg of hair (n = 8), respectively. The immunoassay had no cross-reactivity with dihydrocodeine, ethylmorphine, 6-monoacetylmorphine, pholcodine, propoxyphene, dextromoramide, dextrometorphan at 1 and 10 mg/L, or codeine, morphine, methadone, and its metabolite EDDP. A 1% cross-reactivity was measured for a norbuprenorphine concentration of 50 ng/mL. Finally, the immunoassay was validated by comparing authentic specimens results with those of a validated HPLC/MS method. From the 136 urine samples tested, 93 were positive (68.4%) after the ELISA screening test (cutoff: 0.5 ng/mL) and confirmed by HPLC/MS (buprenorphine concentrations: 0.3-2036 ng/mL). From the 108 blood or serum samples screened, 27 were positive (25%) after the ELISA test with a cutoff value of 0.5 ng/mL (buprenorphine concentrations: 0.2-13.3 ng/mL). Eighteen hair specimens were positive (72%) after the screening (cutoff: 10 pg/mg) and confirmed by LC/MS (buprenorphine concentrations: 40-360 pg/mg). The ELISA method produced false positive results in less than 21% of the cases, but no false negative results were observed with the immunological test. Four potential adulterants (hypochloride 50 mL/L, sodium nitrite 50 g/L, liquid soap 50 mL/L, and sodium chloride 50 g/L) that were added to 10 positive urine specimens (buprenorphine concentrations in the range 5.3-15.6 ng/mL), did not cause a false negative response by the immunoassay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240036     DOI: 10.1016/j.forsciint.2004.02.035

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  11 in total

1.  Validation and application of a method for the determination of buprenorphine, norbuprenorphine, and their glucuronide conjugates in human meconium.

Authors:  Sherri L Kacinko; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Chem       Date:  2007-11-29       Impact factor: 6.986

2.  Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women.

Authors:  Marta Concheiro; Hendreé Jones; Rolley E Johnson; Diaa M Shakleya; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-01-01       Impact factor: 3.205

3.  Evaluation of buprenorphine hydrochloride Pluronic(®) gel formulation in male C57BL/6NCrl mice.

Authors:  Terry L Blankenship-Paris; John W Dutton; David R Goulding; Christopher A McGee; Grace E Kissling; Page H Myers
Journal:  Lab Anim (NY)       Date:  2016-09-21       Impact factor: 12.625

4.  Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry.

Authors:  Marta Concheiro; Diaa M Shakleya; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2009-04-29       Impact factor: 2.395

5.  Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice.

Authors:  Tannia S Clark; David D Clark; Robert F Hoyt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

6.  Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry.

Authors:  Marta Concheiro-Guisan; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2009-02-27       Impact factor: 4.142

7.  Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine.

Authors:  Sherri L Kacinko; Marta Concheiro-Guisan; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2008-08-30       Impact factor: 4.142

8.  Thermal latency studies in opiate-treated mice.

Authors:  Noam Schildhaus; Eliana Trink; Chirs Polson; Louis Detolla; Betty M Tyler; George I Jallo; Sino Tok; Michael Guarnieri
Journal:  J Pharm Bioallied Sci       Date:  2014-01

9.  Rapid Identification of Buprenorphine in Patient Saliva.

Authors:  Stuart Farquharson; Kathryn Dana; Chetan Shende; Zachary Gladding; Jenelle Newcomb; Jessica Dascher; Ismene L Petrakis; Albert J Arias
Journal:  J Anal Bioanal Tech       Date:  2017-06-23

10.  High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Buprenorphine Evaluation in Plasma-Application to Pharmacokinetic Studies in Rabbits.

Authors:  Marta Tikhomirov; Błażej Poźniak; Tomasz Śniegocki
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.